FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT	OF CH	ANGES	IN BENE	FICIAL	OWNER	SHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* SCHAEFFER LEONARD D				2. Issuer Name and Ticker or Trading Symbol scPharmaceuticals Inc. [SCPH]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				uer		
(Last)	PHARMA	First) CEUTICALS INC			X Director 10% Owner 3. Date of Earliest Transaction (Month/Day/Year) 06/09/2020 X Director 10% Owner Officer (give title below) below)														
(Street) BURLIN (City)	IGTON		01803 (Zip)		4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Application) X Form filed by One Reporting Person Form filed by More than One Reporting Person										n			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					ction 2A. Deemed Execution Date,), T	3. 4. Securities Acq Transaction Disposed Of (D) (Code (Instr. 5)			Acquired (A) or		nount of rities eficially ed Following	Forn (D) o	: Direct c r Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									G	Code V	'	Amount (A) or (D)		Price	Tran		Reported Transaction(s) (Instr. 3 and 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year)				ransaction of Eode (Instr. Derivative (Expi	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price Derivat Securit (Instr. 5	ve derivativ	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A) (D)		Date Exer	e rcisable	Exp Dat	piration te	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$7.96	06/09/2020			A		6,124			(1)	06/	09/2030	Common Stock	6,124	\$0.00	6,12	4	D	

Explanation of Responses:

1. This stock option vests in full upon the earlier of (i) June 9, 2021, and (ii) the next annual meeting of the Issuer's stockholders.

Remarks:

/s/ John H. Tucker, attorney-in-06/11/2020 **fact**

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.